Wealth Alliance lifted its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) by 60.0% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,000 shares of the biotechnology company’s stock after acquiring an additional 12,000 shares during the period. Wealth Alliance’s holdings in Heron Therapeutics were worth $112,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of HRTX. Victory Capital Management Inc. raised its holdings in shares of Heron Therapeutics by 30.2% during the fourth quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 4,617 shares during the period. Panagora Asset Management Inc. acquired a new position in Heron Therapeutics during the 4th quarter worth approximately $236,000. Orchard Capital Management LLC raised its stake in Heron Therapeutics by 4.7% during the 4th quarter. Orchard Capital Management LLC now owns 2,243,426 shares of the biotechnology company’s stock worth $3,814,000 after buying an additional 100,603 shares during the period. Diversified Trust Co bought a new position in Heron Therapeutics in the first quarter worth approximately $66,000. Finally, Commonwealth Equity Services LLC grew its stake in Heron Therapeutics by 3.1% in the first quarter. Commonwealth Equity Services LLC now owns 338,526 shares of the biotechnology company’s stock valued at $938,000 after acquiring an additional 10,122 shares during the period. 80.01% of the stock is owned by institutional investors.
Heron Therapeutics Stock Performance
HRTX stock opened at $2.06 on Friday. The company has a market capitalization of $310.35 million, a P/E ratio of -3.38 and a beta of 1.80. Heron Therapeutics, Inc. has a 52-week low of $0.50 and a 52-week high of $3.93. The business has a 50-day simple moving average of $2.33 and a two-hundred day simple moving average of $2.77.
Wall Street Analysts Forecast Growth
HRTX has been the topic of a number of research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 target price on shares of Heron Therapeutics in a research report on Wednesday, August 7th. Rodman & Renshaw initiated coverage on shares of Heron Therapeutics in a research note on Thursday, June 13th. They set a “buy” rating and a $7.00 price target for the company.
Check Out Our Latest Stock Analysis on Heron Therapeutics
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
See Also
- Five stocks we like better than Heron Therapeutics
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- 3 Monster Growth Stocks to Buy Now
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.